Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback